Fred Hutchinson Cancer Center

1. BeiGene, Ltd. $9,529,126 211 payments
2. AstraZeneca Pharmaceuticals LP $7,509,169 15 payments
3. Sanofi US Services Inc. $3,186,279 40 payments
4. BeOne Medicines Ltd. $2,679,399 28 payments
5. AstraZeneca UK Limited $1,181,526 5 payments
6. Celgene Corporation $1,128,901 18 payments
7. Taiho Oncology, Inc. $810,016 15 payments
8. Pfizer Inc. $735,196 30 payments
9. Boehringer Ingelheim Pharma GmbH & Co.KG $685,799 15 payments
10. Incyte Corporation $631,010 101 payments

1. A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment With Ibrutinib and/or Acalabrutinib $6,673,182 66 payments
2. Acalabrutinib for chronic graft versus host disease ESR1813995 $3,988,046 6 payments
3. Acalabrutinib in combination with Venetoclax for previously treated CLL or small lymphocytic lymphoma (SLL) $2,808,470 4 payments
4. Pooled Study for Isatuximab $2,791,779 28 payments
5. A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies $1,873,830 100 payments
6. A Phase 1/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients with Mature B-Cell Malignancies $1,356,793 52 payments
7. A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia $1,049,572 3 payments
8. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) Plus Platinum and Fluoropyrimidine Versus Placebo Plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients Wi $878,317 18 payments
9. A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment $863,496 3 payments
10. A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) $700,563 11 payments

1. Patient care $441,038 50 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.